Forum for Science, Industry and Business
  • Sponsored by:
  • Siemens
  • Siemens
  • Siemens
Search our Site:

Topic (optional):

 

Home Reports Health and Medicine Content

University and health science center in San Antonio collaborate to find chlamydia vaccine

next article
21.02.2007

UTSA/UTHSC successful in mouse models and now move to guinea pigs

 

It's the most common bacteria-related sexually transmitted disease in the United States, so researchers at The University of Texas at San Antonio's South Texas Center for Emerging Infectious Diseases (STCEID) and The University of Texas at San Antonio Health Science Center have partnered to discover a vaccine that will prevent Chlamydia.


According to the Centers for Disease Control and Prevention (CDC), Chlamydia is a common sexually transmitted disease caused by the bacterium, Chlamydia trachomatis, which can damage a woman's reproductive organs. In women, symptoms are usually mild or absent. Serious complications can cause irreversible damage, including infertility, before a woman ever recognizes a problem. In men, Chlamydia complications can also cause discharge from the penis of an infected male.

The most recent report from the CDC indicates 930,000 cases of Chlamydial infection were reported in the United States in 2004. It's estimated annually, that the number of new cases of Chlamydia infection has risen to more than 2.8 million.

After three years of trial-and-error, Ashlesh Murthy, a post-doctoral student in the UTSA Cell and Molecular Biology program has found success in administering a chlamydial prevention vaccine in mouse models. The next step will be to test the vaccine in larger animals, primarily guinea pigs.

"This is a very prevalent disease in women throughout the world and the biggest problem is that most infected women never show any symptoms, so they never get treated," said Murthy. "When Chlamydia is left untreated, it can lead to severe complications including pelvic-inflammatory disease, ectopic pregnancies and infertility."

Murthy's research is guided by Bernard Arulanandam, an associate professor of biology who began studying Chlamydia six years ago.

"With the recent success of the human papilloma virus vaccine, developed to prevent cervical cancer in young women, I think the urgency to develop a Chlamydia prevention vaccine is on the horizon," said Arulanandam.

The UTSA researchers have been working with Guangming Zhong, a professor of microbiology at UTHSC, whose lab has been identifying antigens or proteins in Chlamydia as vaccine candidates and providing them for the UTSA researchers to analyze for their efficacy.

Kris Edward Rodriguez | Source: EurekAlert!
Further information: www.utsa.edu

next article

More articles from Health and Medicine:

nachricht Does hormone treatment predispose patients to breast cancer?
21.11.2008 | CNRS (Délégation Paris Michel-Ange)

nachricht Mechanisms of cardiovascular disease and cancer give clues to new therapies
21.11.2008 | European Science Foundation

B2B Search

Product / Service
Company / Organisation

Latest News

Sustainable garden roofs developed as a new construction material

21.11.2008 | Studies and Analyses

Bees declared the winners in Earthwatch’s ‘irreplaceable species’ battle

21.11.2008 | Ecology, The Environment and Conservation

Hairspray is linked to common genital birth defect

21.11.2008 | Studies and Analyses

Event News

The Automobile – The Transition from Energy Guzzler to Power Supplier

20.11.2008 | Event News

Ministers meet to define the role of space in delivering global objectives

18.11.2008 | Event News

156th Annual Acoustical Society of America (ASA) Meeting in Miami

28.10.2008 | Event News